JNJ-26854165 (Serdemetan)

Catalog No.S1172

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Cited by 4 Publications

BMC Pharmacol Toxicol, 2017, 18(1):40

PubMed: 28577368 ( click the link to review the publication )

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263 ( click the link to review the publication )

Sci Rep, 2014, 4:4664

PubMed: 24722541 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

6 Customer Reviews

Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description

Targets

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. ^[1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. ^[2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KU-19-19 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmnMTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTN{M{[g{txO	MYDTRW5ITVJ?
H4 cell	NXz0c3FrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEnrVIZKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wOlcxPyEQvF2=	NGDLfGpUSU6JRWK=
KGN cell	NVfEbZV2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWruRnZwUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYzODVizszN	M{PtUHNCVkeHUh?=
786-0 cell	NGXLUJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGnvU3JKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44Ojl6OTFOwG0>	M1riW3NCVkeHUh?=
769-P cell	NV7DRmZ5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2DZPWlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlgzOjJ2IN88US=>	MUfTRW5ITVJ?
K5 cell	NUnSXWJTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMU[yOEDPxE1?	M4P6cnNCVkeHUh?=
MLMA cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFMzOTdizszN	MlrCV2FPT0WU
MLMA cell	Mn\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEXGcnVKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI5PzB\|IN88US=>	NGPNRXJUSU6JRWK=
EW-7 cell	Ml;lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVnJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkOyOlk2KM7:TR?=	NUPDOVZ6W0GQR1XS
SW1088 cell	NVvHdGtHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFnCO2lKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDB4NUGg{txO	NXHzWotIW0GQR1XS
MC-IXC cell	MneyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGPH[HJKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDd5OUKg{txO	NYj5ZlF5W0GQR1XS
NCI-H2052 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnS1TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwOVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjB6MUW3JO69VQ>?	NWLOcpFYW0GQR1XS
IGR-1 cell	NYLIZnRmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGlIWi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6xNlAzQCEQvF2=	MkHJV2FPT0WU
DSH1 cell	NWTGWZloT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWTGeYY{UW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPDJ7NjFOwG0>	NXewNohCW0GQR1XS
PA-1 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWDEfW9LUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{ODB3Od88US=>	M2HIeXNCVkeHUh?=
SK-MEL-3 cell	Mo\xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OTJyNzFOwG0>	M4faNXNCVkeHUh?=
SW900 cell	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHNYQTByIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz60PFI2PSEQvF2=	MofLV2FPT0WU
CAKI-1 cell	M1uz[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MonKTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzPzN6IN88US=>	Mk\oV2FPT0WU
ES1 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4n1PWlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz61Nlg6PyEQvF2=	NF7CcHNUSU6JRWK=
SK-N-DZ cell	NFK4W3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M{OyW2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3EXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjJ3OUWg{txO	Mn\lV2FPT0WU
RH-1 cell	Mn\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NIjS[mVKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY5PDZ\|IN88US=>	NVTROVFqW0GQR1XS
ES8 cell	NIrERnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGfifndKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOlk4ODJizszN	NEn5cmJUSU6JRWK=
NEC8 cell	MkfQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEnae3VKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc3QTh{IN88US=>	NHH0TYVUSU6JRWK=
LNCaP-Clone-FGC cell	NUXKOnhOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXXxdXdGUW6qaXLpeIlwdiCxZjDoeY1idiCOTlPhVE1EdG:wZT3GS2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh\|NUO2JO69VQ>?	NVjzNZVLW0GQR1XS
HCE-4 cell	NXLJT4VnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYD0OWg2UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0>	MmnaV2FPT0WU
U-118-MG cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmTwTY5pcWKrdHnvckBw\iCqdX3hckBWNTFzOD3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODFyNk[g{txO	MlHYV2FPT0WU
GI-ME-N cell	NF;JRVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVTFSoFTUW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yOEe5OkDPxE1?	NGHyUWdUSU6JRWK=
LB1047-RCC cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVqwfFBNUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xOlE1OyEQvF2=	MULTRW5ITVJ?
HT-1080 cell	NV70ZWw{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4Tj[2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTl7MkGg{txO	MUfTRW5ITVJ?
NB69 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkHMTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6zOVA1PyEQvF2=	M17iRXNCVkeHUh?=
NCI-H1693 cell	MlrCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MknITY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR2OEm1JO69VQ>?	NIHxcWdUSU6JRWK=
HSC-3 cell	MnnNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1\iPGlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ6QTN\|IN88US=>	M1\lc3NCVkeHUh?=
MDA-MB-231 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV3OEm5JO69VQ>?	NEnNNmRUSU6JRWK=
HOS cell	NUfOOVExT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUXafmhQUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5PjNizszN	Mk\aV2FPT0WU
BT-549 cell	MlvaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEWyVJpKdmirYnn0bY9vKG:oIHj1cYFvKEKWLUW0PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPzh6NzFOwG0>	NYqwcosxW0GQR1XS
NB17 cell	NGTI[YtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHXHXmdKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QTd4IN88US=>	NFfEdVJUSU6JRWK=
5637 cell	MoLQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXzvXmdWUW6qaXLpeIlwdiCxZjDoeY1idiB3NkO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QTZ3MjFOwG0>	Mli0V2FPT0WU
OVCAR-8 cell	Ml;YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2LPPGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTJ2M{[g{txO	M1\mR3NCVkeHUh?=
G-402 cell	NVnqeIM1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M17pNGlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk{ODN3IN88US=>	NFnXbHpUSU6JRWK=
BB30-HNC cell	M2nSRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYXQ[3ZnUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwMEeyNVgh\|ryP	MmTIV2FPT0WU
HCC1806 cell	M1HweGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXG1d4ROUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPFA3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yOEOzPUDPxE1?	NVLIboZUW0GQR1XS
COLO-800 cell	NWHpRWtYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MknkTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTJ4NDFOwG0>	NInnWnlUSU6JRWK=
FADU cell	Ml32S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHLmXVhKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM3PTV5IN88US=>	MlL5V2FPT0WU
NCI-H1651 cell	NYXodYZVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M37FeGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5\|OUSwPUDPxE1?	MkTLV2FPT0WU
AGS cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{DlSmlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT60O\|cyOSEQvF2=	MYnTRW5ITVJ?
CHP-212 cell	M3HZWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6PDB7IN88US=>	NEC2WlFUSU6JRWK=
YAPC cell	MmfyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEOxRoRKdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=>	MWfTRW5ITVJ?
GOTO cell	M1zVW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGdQXE9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS5OVc3KM7:TR?=	M{LS[3NCVkeHUh?=
KYSE-510 cell	MoezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Ml62TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTFzIN88US=>	MnzIV2FPT0WU
NCI-H2342 cell	NGfBNHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIiyV2FKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNUOyO\|gh\|ryP	Mn70V2FPT0WU
BFTC-905 cell	M4H2XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmTrTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjJ6M{Wg{txO	NHTzT4dUSU6JRWK=
EW-16 cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1XjVWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlczODl\|IN88US=>	MnjwV2FPT0WU
SK-MEL-30 cell	M13YSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzR3NEOg{txO	NXO0cW5xW0GQR1XS
HLE cell	NWPOUo9xT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlnWTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke3OFg6KM7:TR?=	MVTTRW5ITVJ?
T98G cell	NFrCOXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MUPJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5OlM2KM7:TR?=	MlfkV2FPT0WU
HUTU-80 cell	NXTTTWt6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYnJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg1OjJ6IN88US=>	NU\ZTGFtW0GQR1XS
NOS-1 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Ml3nTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVQ4PjZizszN	MonmV2FPT0WU
SW780 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3LGOmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk3QTR7IN88US=>	M2ro[XNCVkeHUh?=
KYSE-180 cell	M1zncmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXnPWIs{UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE5OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUe2OVQh\|ryP	MWnTRW5ITVJ?
MDA-MB-361 cell	NYrhZXNQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYTlO4pIUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT65PFY1PyEQvF2=	MkPYV2FPT0WU
SNU-C2B cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlrLTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF\|ODFOwG0>	MUXTRW5ITVJ?
NCI-H661 cell	NXTIVZNQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlnHTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvODZ7NDFOwG0>	MXHTRW5ITVJ?
OE33 cell	NESzOWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NEf3XlJKdmirYnn0bY9vKG:oIHj1cYFvKE:HM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE1Ozh7IN88US=>	NWDxUnBTW0GQR1XS
TYK-nu cell	M1Lq[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWTJcohq[mm2aX;uJI9nKGi3bXHuJHR[Uy2wdTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNlE5PjNizszN	MXjTRW5ITVJ?
COLO-792 cell	NHPoPZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUfKclBtUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwMkWyNVkh\|ryP	MV\TRW5ITVJ?
HEL cell	Ml;1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnzrTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkK2O\|Yh\|ryP	MkCwV2FPT0WU
D-566MG cell	M2\3NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NX2zNXM1UW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5\|M{S5NUDPxE1?	NYPaeI1IW0GQR1XS
U031 cell	NUH1d3p2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3fRXmlvcGmkaYTpc44hd2ZiaIXtZY4hXTB\|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uOFE5OTZizszN	MWnTRW5ITVJ?
COR-L23 cell	NHT1fYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGGyU4xKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR\|M{S2JO69VQ>?	MYDTRW5ITVJ?
NCI-H2452 cell	MoXPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEOzU2hKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQ2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwNUKyPFEh\|ryP	NIDiUJZUSU6JRWK=
BB65-RCC cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYLJcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PDV7IN88US=>	NGnje3VUSU6JRWK=
CAL-33 cell	NUGxZpR7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFPafVlKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjV4NkWg{txO	NWTPblhXW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo

JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells Concentrations: 0-10 μM Incubation Time: 72 hours Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK (Only for Reference)
Animal Research:^[4]	+ Expand Animal Models: CB17SC scid^-/- female mice. Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water. Dosages: ≤20 mg/kg Administration: Administered via p.o. (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
Concentrations: 0-10 μM
Incubation Time: 72 hours
Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
(Only for Reference)

Animal Research:^[4]

+ Expand

Animal Models: CB17SC scid^-/- female mice.
Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
Dosages: ≤20 mg/kg
Administration: Administered via p.o.
(Only for Reference)

References

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

+ Expand

Solubility (25°C)

In vitro	DMSO	66 mg/mL (200.96 mM)
	Ethanol	2 mg/mL (6.08 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Molecular Weight	328.41
Formula	C₂₁H₂₀N₄
CAS No.	881202-45-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00676910	Completed	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1
NCT00676910	Completed	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p53 Signaling Pathway Map

Related p53 Products0

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
RITA (NSC 652287)

RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

Features:Inducer of DNA cross-links, not a DNA intercalator.
Pifithrin-α (PFTα) HBr

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.
Tenovin-1

Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2.
Tenovin-6

Tenovin-6 is a small molecule activator of p53 transcriptional activity.
NSC 319726

NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells.

Features:An allele-specific p53 mutant reactivator.
Pifithrin-μ

Pifithrin-μ is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.
Z-VAD-FMK

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Features:A key compound for apoptosis studies.

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)

Cited by 4 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

p53 Signaling Pathway Map

Related p53 Products0

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)

Cited by 4 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

p53 Signaling Pathway Map

Related p53 Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)